Protein misfolding is involved in a large number of diseases, among which cystic fibrosis.
Complex intra-and inter-domain folding defects associated with mutations in the cystic …

Ligand-induced protein degradation has emerged as a compelling approach to promote the
targeted elimination of proteins from cells by directing these proteins to the ubiquitin …

Proteolysis targeting chimeras (PROTACs) represent a new class of promising therapeutic
modalities. PROTACs hijack E3 ligases and the ubiquitin-proteasome system (UPS), leading …

Targeted protein degradation (TPD) has emerged as a powerful tool in drug discovery for
the perturbation of protein levels using heterobifunctional small molecules. E3 ligase …

Somatic mutations in spliceosome proteins lead to dysregulated RNA splicing and are
observed in a variety of cancers. These genetic aberrations may offer a potential intervention …

Protein–protein interactions (PPIs) govern all biological processes. Some small molecules
modulate PPIs through induced protein proximity. In particular, molecular glue degraders …

Thalidomide and its derivatives are powerful cancer therapeutics that are among the best-
understood molecular glue degraders (MGDs). These drugs selectively reprogram the E3 …

Dissection of complex biological systems requires target-specific control of the function or
abundance of proteins. Genetic perturbations are limited by off-target effects …

Targeted protein degradation induced by heterobifunctional compounds and molecular
glues presents an exciting avenue for chemical probe and drug discovery. To date, small …

Developing PROTACs to redirect the ubiquitination activity of E3 ligases and potently
degrade a target protein within cells can be a lengthy and unpredictable process, and it …